The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2024 | Patients with CLL on continuous ibrutinib have a life expectancy comparable to healthy individuals
Paolo Ghia, MD, Vita-Salute San Raffaele University, Milan, Italy, discusses a study showing that patients in Europe with chronic lymphocytic leukemia (CLL) treated with continuous ibrutinib have a life expectancy comparable to that of healthy individuals, regardless of age at which they are diagnosed. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Research Funding: BeiGene, BMS, Lilly/Loxo Oncology, AstraZeneca, Janssen, MSD, AbbVie, Roche; Consultancy: BeiGene, BMS, Lilly/Loxo Oncology, AstraZeneca, Janssen, MSD, AbbVie, Roche; Honoraria: BeiGene, BMS, Lilly/Loxo Oncology, AstraZeneca, Janssen, MSD, AbbVie, Roche.
